These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 24391492)

  • 21. Requirement for invariant chain in macrophages for Mycobacterium tuberculosis replication and CD1d antigen presentation.
    Sillé FC; Martin C; Jayaraman P; Rothchild A; Fortune S; Besra GS; Behar SM; Boes M
    Infect Immun; 2011 Aug; 79(8):3053-63. PubMed ID: 21576321
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of genetically engineered iNKT cells expressing TCRs specific for the M. tuberculosis 38-kDa antigen.
    Jiang ZM; Luo W; Wen Q; Liu SD; Hao PP; Zhou CY; Zhou MQ; Ma L
    J Transl Med; 2015 May; 13():141. PubMed ID: 25943357
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD1d-independent activation of mouse and human iNKT cells by bacterial superantigens.
    Hayworth JL; Mazzuca DM; Maleki Vareki S; Welch I; McCormick JK; Haeryfar SM
    Immunol Cell Biol; 2012 Aug; 90(7):699-709. PubMed ID: 22041925
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Invariant natural killer T cells generated from human adult hematopoietic stem-progenitor cells are poly-functional.
    Sun W; Wang Y; East JE; Kimball AS; Tkaczuk K; Kesmodel S; Strome SE; Webb TJ
    Cytokine; 2015 Mar; 72(1):48-57. PubMed ID: 25569376
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IL-10 down-regulates costimulatory molecules on Mycobacterium tuberculosis-pulsed macrophages and impairs the lytic activity of CD4 and CD8 CTL in tuberculosis patients.
    de la Barrera S; Aleman M; Musella R; Schierloh P; Pasquinelli V; Garcia V; Abbate E; Sasiain Mdel C
    Clin Exp Immunol; 2004 Oct; 138(1):128-38. PubMed ID: 15373915
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relative levels of M-CSF and GM-CSF influence the specific generation of macrophage populations during infection with Mycobacterium tuberculosis.
    Higgins DM; Sanchez-Campillo J; Rosas-Taraco AG; Higgins JR; Lee EJ; Orme IM; Gonzalez-Juarrero M
    J Immunol; 2008 Apr; 180(7):4892-900. PubMed ID: 18354213
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination of NKT14m and Low Dose IL-12 Promotes Invariant Natural Killer T Cell IFN-γ Production and Tumor Control.
    Guan P; Schaub R; Nichols KE; Das R
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708464
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Type I IFN induces IL-10 production in an IL-27-independent manner and blocks responsiveness to IFN-γ for production of IL-12 and bacterial killing in Mycobacterium tuberculosis-infected macrophages.
    McNab FW; Ewbank J; Howes A; Moreira-Teixeira L; Martirosyan A; Ghilardi N; Saraiva M; O'Garra A
    J Immunol; 2014 Oct; 193(7):3600-12. PubMed ID: 25187652
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human Macrophages Exhibit GM-CSF Dependent Restriction of
    Mishra A; Singh VK; Jagannath C; Subbian S; Restrepo BI; Gauduin MC; Khan A
    Front Immunol; 2022; 13():859116. PubMed ID: 35634283
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histamine receptor 2 modifies iNKT cell activity within the inflamed lung.
    Ferstl R; Frei R; Barcik W; Schiavi E; Wanke K; Ziegler M; Rodriguez-Perez N; Groeger D; Konieczna P; Zeiter S; Nehrbass D; Lauener R; Akdis CA; O'Mahony L
    Allergy; 2017 Dec; 72(12):1925-1935. PubMed ID: 28618071
    [TBL] [Abstract][Full Text] [Related]  

  • 31. invariant Natural Killer T Cells Modulate the Peritoneal Macrophage Response to Polymicrobial Sepsis.
    Heffernan DS; Chun TT; Monaghan SF; Chung CS; Ayala A
    J Surg Res; 2024 Aug; 300():211-220. PubMed ID: 38824851
    [TBL] [Abstract][Full Text] [Related]  

  • 32. T Cell Production of GM-CSF Protects the Host during Experimental Tuberculosis.
    Robinson RT
    mBio; 2017 Dec; 8(6):. PubMed ID: 29233902
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD1d-Dependent iNKT Cells Control DSS-Induced Colitis in a Mouse Model of IFNγ-Mediated Hyperinflammation by Increasing IL22-Secreting ILC3 Cells.
    Park HJ; Lee SW; Van Kaer L; Hong S
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33513946
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A gamma interferon independent mechanism of CD4 T cell mediated control of M. tuberculosis infection in vivo.
    Gallegos AM; van Heijst JW; Samstein M; Su X; Pamer EG; Glickman MS
    PLoS Pathog; 2011 May; 7(5):e1002052. PubMed ID: 21625591
    [TBL] [Abstract][Full Text] [Related]  

  • 35. iNKT Cells Suppress Pathogenic NK1.1
    Lee SW; Park HJ; Cheon JH; Wu L; Van Kaer L; Hong S
    Front Immunol; 2018; 9():2168. PubMed ID: 30333822
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alpha-galactosylceramide as a therapeutic agent for pulmonary Mycobacterium tuberculosis infection.
    Sada-Ovalle I; Sköld M; Tian T; Besra GS; Behar SM
    Am J Respir Crit Care Med; 2010 Sep; 182(6):841-7. PubMed ID: 20508216
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide.
    Hogan AE; O'Reilly V; Dunne MR; Dere RT; Zeng SG; O'Brien C; Amu S; Fallon PG; Exley MA; O'Farrelly C; Zhu X; Doherty DG
    Clin Immunol; 2011 Aug; 140(2):196-207. PubMed ID: 21493160
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Invariant NKT cells inhibit development of the Th17 lineage.
    Mars LT; Araujo L; Kerschen P; Diem S; Bourgeois E; Van LP; Carrié N; Dy M; Liblau RS; Herbelin A
    Proc Natl Acad Sci U S A; 2009 Apr; 106(15):6238-43. PubMed ID: 19325124
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The cytokines IL-21 and GM-CSF have opposing regulatory roles in the apoptosis of conventional dendritic cells.
    Wan CK; Oh J; Li P; West EE; Wong EA; Andraski AB; Spolski R; Yu ZX; He J; Kelsall BL; Leonard WJ
    Immunity; 2013 Mar; 38(3):514-27. PubMed ID: 23453633
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial.
    Exley MA; Friedlander P; Alatrakchi N; Vriend L; Yue S; Sasada T; Zeng W; Mizukami Y; Clark J; Nemer D; LeClair K; Canning C; Daley H; Dranoff G; Giobbie-Hurder A; Hodi FS; Ritz J; Balk SP
    Clin Cancer Res; 2017 Jul; 23(14):3510-3519. PubMed ID: 28193627
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.